Biosimilars Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019-2029, Segmented By Product ; By Disease Indication ; By Distribution Channel ; By Region,

Description

Global Biosimilars Market Size Zooming to Touch USD 115.4 Billion by 2029

Global biosimilar market size is flourishing owing to various blockbuster biological drugs' patent expirations, price reductions, an increase in the prevalence of chronic diseases, and cost-cutting measures taken by governments and third-party payers.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimates global biosimilars market size at USD 28.88 billion in 2022. During the forecast period between 2023 and 2029, BlueWeave expects global biosimilars market size to grow at a robust CAGR of 21.3% reaching a value of USD 115.39 billion by 2029. The affordability of biosimilars in treating a range of chronic diseases that are widespread among the world's population is what is fueling the growth of the global biosimilars market. Due to the rising prevalence of chronic diseases in the population and the recent regulatory authority approval of numerous biosimilars in numerous countries, it is expected that the adoption of biosimilars will increase quickly. Globally, there is a growing demand for biosimilars as people become more aware of their availability and effectiveness in treating a range of disorders. Since kidney failure, diabetes, cancer, and cardiovascular disease are among the many chronic diseases for which biosimilars are an effective treatment option, the market is expected to grow over the coming years. However, strict policies and market entry barriers for new players are likely to limit global market growth.

Global Biosimilars Market - Overview

A biosimilar is a biologic medical product that is extremely similar to an already-approved biologic. These biosimilars are approved based on their efficacy, quality, safety, and pharmaceutical quality standards, which apply to all biological medicines. Biosimilars are generic versions of biologics that have reached the end of their patent life cycle. The patent expiration of well-known biologics is expected to drive the global biosimilar market. Increased approval and sales of biosimilars have resulted in a significant drop in sales of biologics with stable or growing demand. The global burden of chronic diseases is increasing. The rise in the prevalence of chronic diseases can be attributed largely to the aging population and people's changing lifestyles. Some of the most prevalent chronic diseases include diabetes, hypertension, stroke, respiratory and oral illnesses, obesity, arthritis, and cancer. On the other hand, the treatment of cancer and rheumatoid arthritis with biosimilar monoclonal antibodies is widely used.

Biosimilars are being developed by several biopharmaceutical companies around the world. The global biosimilars market has the potential to expand quickly. A large number of biological drugs are likely to lose their patent protection in the coming years. As a result, lower healthcare costs and government regulatory structure changes are expected to drive the market during the forecast period. The use of monoclonal antibodies to treat COVID-19 has rekindled interest in the biosimilars market. Manufacturers are expanding their research capabilities to develop better immunotherapy drugs. These drugs have the potential to reduce the number of side effects experienced by cancer patients. A positive effect on the market is also being produced by the expansion of insurance coverage for biosimilars.

Opportunity: Increasing government spending on healthcare

The federal government's increased funding could fuel the market's expansion. Additionally, the growth and expansion of the healthcare sector, driven by both public and private actors, particularly in developing economies, will present profitable opportunities for the biosimilars market. The market growth rate is also being supported by the government healthcare facilities' growing acceptance of bioidentical hormone replacement therapy. The introduction of technologically advanced products in hospitals, rising investment in the development of advanced, and increased emphasis on women's health care and the treatment of hormonal imbalances are other factors that have a positive impact on the market growth rate.

Challenge: Expensive research and development of biopharmaceutical products

High costs associated with R&D capabilities, high manufacturing costs, and difficulties associated with medical procedures, on the other hand, are expected to stymie market growth. Furthermore, during the forecast period of 2022-2029, the market is expected to face challenges due to a lack of favorable reimbursement scenarios and technology penetration in developing economies, as well as a lack of definitive approval standards and suitable infrastructure in low- and middle-income countries.

Impact of COVID-19 on Global Biosimilars Market

The COVID-19 outbreak affects several international industries, including the market for biosimilars. Administrative bodies everywhere implemented several measures, including lockdowns and strict social seclusion, to slow the Covid-19 pandemic's rapid spread. The biosimilars market was harmed by the widespread closing of manufacturing facilities in the early stages of the pandemic. The pandemic had a significant negative impact on small and medium-sized businesses, which are the primary technology suppliers to the biosimilars industry. The lockdown measures implemented during the early stages of the epidemic's spread limited the movement of people and goods, which affected the biosimilar market as well.

Global Biosimilars Market - By Distribution Channel

The global biosimilar market is divided into three segments based on distribution channels: hospital pharmacies, retail pharmacies, and online pharmacies. During the forecast period between 2023 and 2029, the retail pharmacies segment is expected to lead the global biosimilars market by distribution channel.

Competitive Landscape

Global biosimilars market is fiercely competitive. Prominent players in global biosimilars market include Novartis AG, Orion Pharma AB, Pfizer Inc., Samsung Bioepis, Coherus BioSciences, Inc., Amgen Inc., Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Bristol-Myers Squibb Company, Merck KGaA, Teva Pharmaceutical Industries Ltd., Biocon, Bayer AG, AbbVie Inc., Allergan, Dr. Reddy's Laboratories Ltd., Boehringer Ingelheim International GmbH, and Biogen. These companies use various strategies, including increasing investments in their R&D activities, mergers, and acquisitions, joint ventures, collaborations, licensing agreements, and new product and service releases to further strengthen their position in global biosimilars market.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of Global Biosimilars Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global Biosimilars Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Product Code: BWC22532

1. Research Framework

1.1. Research Objective
1.2. Product Overview
1.3. Market Segmentation

2. Executive Summary

3. Global Biosimilars Market Insights

3.1. Industry Value Chain Analysis
3.2. DROC Analysis
- 3.2.1. Growth Drivers
  - 3.2.1.1. Rising prevalence of autoimmune diseases
  - 3.2.1.2. Increasing adoption of biosimilars
  - 3.2.1.3. Rising cost effectiveness of biosimilars
- 3.2.2. Restraints
  - 3.2.2.1. Complexities in manufacturing
- 3.2.3. Opportunity
  - 3.2.3.1. Rising research and development proficiencies
  - 3.2.3.2. Rising government investments on healthcare infrastructure
- 3.2.4. Challenges
  - 3.2.4.1. Intense Competition
  - 3.2.4.2. High cost of R&D
3.3. Technology Advancements/Recent Developments
3.4. Regulatory Framework
3.5. Porter's Five Forces Analysis
- 3.5.1. Bargaining Power of Suppliers
- 3.5.2. Bargaining Power of Buyers
- 3.5.3. Threat of New Entrants
- 3.5.4. Threat of Substitutes
- 3.5.5. Intensity of Rivalry

4. Global Biosimilars Market Overview

4.1. Market Size & Forecast, 2019-2029
- 4.1.1. By Value (USD Billion)
4.2. Market Share & Forecast
- 4.2.1. By Product
  - 4.2.1.1. Monoclonal Antibodies
  - 4.2.1.1.1. Infliximab
  - 4.2.1.1.2. Rituximab
  - 4.2.1.1.3. Trastuzumab
  - 4.2.1.2. Insulin
  - 4.2.1.3. Interferon
  - 4.2.1.4. Etanercept
  - 4.2.1.5. Glucagon
  - 4.2.1.6. Calcitonin
- 4.2.2. By Disease Indication
  - 4.2.2.1. Cancer
  - 4.2.2.2. Auto-Immune Diseases
  - 4.2.2.3. Chronic Diseases
  - 4.2.2.4. Blood Disorders
  - 4.2.2.5. Others
- 4.2.3. By Distribution Channel
  - 4.2.3.1. Hospital Pharmacies
  - 4.2.3.2. Retail Pharmacies
  - 4.2.3.3. Online Pharmacies
- 4.2.4. By Region
  - 4.2.4.1. North America
  - 4.2.4.2. Europe
  - 4.2.4.3. Asia Pacific (APAC)
  - 4.2.4.4. Latin America
  - 4.2.4.5. Middle East and Africa (MEA)

5. North America Biosimilars Market

5.1.1. Market Size & Forecast, 2019-2029
5.1.2. By Value (USD Billion)

5.2. Market Share & Forecast
- 5.2.1. By Product
- 5.2.2. By Disease Indication
- 5.2.3. By Distribution Channel
- 5.2.4. By Country
  - 5.2.4.1. United States
  - 5.2.4.1.1. By Product
  - 5.2.4.1.2. By Disease Indication
  - 5.2.4.1.3. By Distribution Channel
  - 5.2.4.2. Canada
  - 5.2.4.2.1. By Product
  - 5.2.4.2.2. By Disease Indication
  - 5.2.4.2.3. By Distribution Channel

6. Europe Biosimilars Market

6.1. Market Size & Forecast, 2019-2029
- 6.1.1. By Value (USD Billion)
6.2. Market Share & Forecast
- 6.2.1. By Product
- 6.2.2. By Disease Indication
- 6.2.3. By Distribution Channel
- 6.2.4. By Country
  - 6.2.4.1. Germany
  - 6.2.4.1.1. By Product
  - 6.2.4.1.2. By Disease Indication
  - 6.2.4.1.3. By Distribution Channel
  - 6.2.4.2. United Kingdom
  - 6.2.4.2.1. By Product
  - 6.2.4.2.2. By Disease Indication
  - 6.2.4.2.3. By Distribution Channel
  - 6.2.4.3. Italy
  - 6.2.4.3.1. By Product
  - 6.2.4.3.2. By Disease Indication
  - 6.2.4.3.3. By Distribution Channel
  - 6.2.4.4. France
  - 6.2.4.4.1. By Product
  - 6.2.4.4.2. By Disease Indication
  - 6.2.4.4.3. By Distribution Channel
  - 6.2.4.5. Spain
  - 6.2.4.5.1. By Product
  - 6.2.4.5.2. By Disease Indication
  - 6.2.4.5.3. By Distribution Channel
  - 6.2.4.6. The Netherlands
  - 6.2.4.6.1. By Product
  - 6.2.4.6.2. By Disease Indication
  - 6.2.4.6.3. By Distribution Channel
  - 6.2.4.7. Belgium
  - 6.2.4.7.1. By Product
  - 6.2.4.7.2. By Disease Indication
  - 6.2.4.7.3. By Distribution Channel
  - 6.2.4.8. NORDIC Countries
  - 6.2.4.8.1. By Product
  - 6.2.4.8.2. By Disease Indication
  - 6.2.4.8.3. By Distribution Channel
  - 6.2.4.9. Rest of Europe
  - 6.2.4.9.1. By Product
  - 6.2.4.9.2. By Disease Indication
  - 6.2.4.9.3. By Distribution Channel

7. Asia Pacific Biosimilars Market

7.1. Market Size & Forecast, 2019-2029
- 7.1.1. By Value (USD Billion)
7.2. Market Share & Forecast
- 7.2.1. By Product
- 7.2.2. By Disease Indication
- 7.2.3. By Distribution Channel
- 7.2.4. By Country
  - 7.2.4.1. China
  - 7.2.4.1.1. By Product
  - 7.2.4.1.2. By Disease Indication
  - 7.2.4.1.3. By Distribution Channel
  - 7.2.4.2. India
  - 7.2.4.2.1. By Product
  - 7.2.4.2.2. By Disease Indication
  - 7.2.4.2.3. By Distribution Channel
  - 7.2.4.3. Japan
  - 7.2.4.3.1. By Product
  - 7.2.4.3.2. By Disease Indication
  - 7.2.4.3.3. By Distribution Channel
  - 7.2.4.4. South Korea
  - 7.2.4.4.1. By Product
  - 7.2.4.4.2. By Disease Indication
  - 7.2.4.4.3. By Distribution Channel
  - 7.2.4.5. Australia & New Zealand
  - 7.2.4.5.1. By Product
  - 7.2.4.5.2. By Disease Indication
  - 7.2.4.5.3. By Distribution Channel
  - 7.2.4.6. Indonesia
  - 7.2.4.6.1. By Product
  - 7.2.4.6.2. By Disease Indication
  - 7.2.4.6.3. By Distribution Channel
  - 7.2.4.7. Malaysia
  - 7.2.4.7.1. By Product
  - 7.2.4.7.2. By Disease Indication
  - 7.2.4.7.3. By Distribution Channel
  - 7.2.4.8. Singapore
  - 7.2.4.8.1. By Product
  - 7.2.4.8.2. By Disease Indication
  - 7.2.4.8.3. By Distribution Channel
  - 7.2.4.9. Philippines
  - 7.2.4.9.1. By Product
  - 7.2.4.9.2. By Disease Indication
  - 7.2.4.9.3. By Distribution Channel
  - 7.2.4.10. Vietnam
  - 7.2.4.10.1. By Product
  - 7.2.4.10.2. By Disease Indication
  - 7.2.4.10.3. By Distribution Channel
  - 7.2.4.11. Rest of Asia Pacific
  - 7.2.4.11.1. By Product
  - 7.2.4.11.2. By Disease Indication
  - 7.2.4.11.3. By Distribution Channel

8. Latin America Biosimilars Market

8.1. Market Size & Forecast, 2019-2029
- 8.1.1. By Value (USD Billion)
8.2. Market Share & Forecast
- 8.2.1. By Product
- 8.2.2. By Disease Indication
- 8.2.3. By Distribution Channel
- 8.2.4. By Country
  - 8.2.4.1. Brazil
  - 8.2.4.1.1. By Product
  - 8.2.4.1.2. By Disease Indication
  - 8.2.4.1.3. By Distribution Channel
  - 8.2.4.2. Mexico
  - 8.2.4.2.1. By Product
  - 8.2.4.2.2. By Disease Indication
  - 8.2.4.2.3. By Distribution Channel
  - 8.2.4.3. Argentina
  - 8.2.4.3.1. By Product
  - 8.2.4.3.2. By Disease Indication
  - 8.2.4.3.3. By Distribution Channel
  - 8.2.4.4. Peru
  - 8.2.4.4.1. By Product
  - 8.2.4.4.2. By Disease Indication
  - 8.2.4.4.3. By Distribution Channel
  - 8.2.4.5. Colombia
  - 8.2.4.5.1. By Product
  - 8.2.4.5.2. By Disease Indication
  - 8.2.4.5.3. By Distribution Channel
  - 8.2.4.6. Rest of Latin America
  - 8.2.4.6.1. By Product
  - 8.2.4.6.2. By Disease Indication
  - 8.2.4.6.3. By Distribution Channel

9. Middle East & Africa Biosimilars Market

9.1. Market Size & Forecast, 2019-2029
- 9.1.1. By Value (USD Billion)
9.2. Market Share & Forecast
- 9.2.1. By Product
- 9.2.2. By Disease Indication
- 9.2.3. By Distribution Channel
- 9.2.4. By Country
  - 9.2.4.1. Saudi Arabia
  - 9.2.4.1.1. By Product
  - 9.2.4.1.2. By Disease Indication
  - 9.2.4.1.3. By Distribution Channel
  - 9.2.4.2. UAE
  - 9.2.4.2.1. By Product
  - 9.2.4.2.2. By Disease Indication
  - 9.2.4.2.3. By Distribution Channel
  - 9.2.4.3. Qatar
  - 9.2.4.3.1. By Product
  - 9.2.4.3.2. By Disease Indication
  - 9.2.4.3.3. By Distribution Channel
  - 9.2.4.4. Kuwait
  - 9.2.4.4.1. By Product
  - 9.2.4.4.2. By Disease Indication
  - 9.2.4.4.3. By Distribution Channel
  - 9.2.4.5. Iran
  - 9.2.4.5.1. By Product
  - 9.2.4.5.2. By Disease Indication
  - 9.2.4.5.3. By Distribution Channel
  - 9.2.4.6. South Africa
  - 9.2.4.6.1. By Product
  - 9.2.4.6.2. By Disease Indication
  - 9.2.4.6.3. By Distribution Channel
  - 9.2.4.7. Nigeria
  - 9.2.4.7.1. By Product
  - 9.2.4.7.2. By Disease Indication
  - 9.2.4.7.3. By Distribution Channel
  - 9.2.4.8. Kenya
  - 9.2.4.8.1. By Product
  - 9.2.4.8.2. By Disease Indication
  - 9.2.4.8.3. By Distribution Channel
  - 9.2.4.9. Egypt
  - 9.2.4.9.1. By Product
  - 9.2.4.9.2. By Disease Indication
  - 9.2.4.9.3. By Distribution Channel
  - 9.2.4.10. Morocco
  - 9.2.4.10.1. By Product
  - 9.2.4.10.2. By Disease Indication
  - 9.2.4.10.3. By Distribution Channel
  - 9.2.4.11. Algeria
  - 9.2.4.11.1. By Product
  - 9.2.4.11.2. By Disease Indication
  - 9.2.4.11.3. By Distribution Channel
  - 9.2.4.12. Rest of Middle East & Africa
  - 9.2.4.12.1. By Product
  - 9.2.4.12.2. By Disease Indication
  - 9.2.4.12.3. By Distribution Channel

10. Competitive Landscape

10.1. List of Key Players and Their Offerings
10.2. Global Biosimilars Company Market Share Analysis, 2022
10.3. Competitive Benchmarking, By Operating Parameters
10.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, and others)

11. Impact of Covid-19 on Global Biosimilars Market

12. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)

12.1. Novartis AG
12.2. Orion Pharma AB
12.3. Pfizer Inc.
12.4. Samsung Bioepis
12.5. Coherus BioSciences, Inc.
12.6. Amgen Inc.
12.7. Eli Lilly and Company.
12.8. Takeda Pharmaceutical Company Limited
12.9. Bristol-Myers Squibb Company
12.10. Merck KGaA
12.11. Teva Pharmaceutical Industries Ltd.
12.12. Biocon
12.13. Bayer AG
12.14. AbbVie Inc.
12.15. Allergan
12.16. Dr. Reddy's Laboratories Ltd.
12.17. Boehringer Ingelheim International GmbH
12.18. Biogen
12.19. Other Prominent Players

13. Key Strategic Recommendations

14. Research Methodology

14.1. Qualitative Research
- 14.1.1. Primary & Secondary Research
14.2. Quantitative Research
14.3. Market Breakdown & Data Triangulation
- 14.3.1. Secondary Research
- 14.3.2. Primary Research
14.4. Breakdown of Primary Research Respondents, By Region
14.5. Assumptions & Limitations